Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective

Journal of Cancer Policy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles